Hematology moves fast, data shifts, standards evolve, and the right next step isn’t always clear. LL&M Great Debates was built for the gray area between what’s known and what’s still being tested. 

Across leukemia, lymphoma, myeloma, and chronic lymphocytic leukemia, experts take opposing positions on key questions in hematologic malignancy care. Each debate explores the evidence and challenges assumptions, examining how new data applies to real-world practice. The discussions go beyond presentations to expose the reasons behind each approach and help you weigh the data in context to gain a deeper understanding of treatment decisions. 

Debates form the foundation of the program, complemented by roundtables, case-based discussions, and audience Q&A. Every session is designed to clarify uncertainty in disease management and turn emerging evidence into practical guidance you can use the next day with your patients. Attendees often find that the dialogue helps define what matters most in their daily practice and informs how they interpret the latest research. 

This conference covers the full spectrum of blood cancers, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenström macroglobulinemia (WM), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). Each topic is discussed by leaders in the field who bring both research and clinical perspectives to the table. 

Whether you are looking to update your clinical knowledge, earn CE credit, or connect with peers, LL&M Great Debates series provides an interactive environment focused on improvements in patient outcomes.